Search

everythinglearnresearchcommunity

for

Search:↓

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Some patients on immune therapy for melanoma may develop scarring hair loss, but cancer treatment remains effective.

Immune therapy for cancer can cause hair loss scars in some patients.

Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Nivolumab can cause hair loss as a rare side effect.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.

A gel from stem cells can reduce baldness caused by fluconazole in rats.

Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Hair loss in a drug reaction case involved both a common shedding phase and an immune attack on hair follicle stem cells.

Cancer treatments often cause hair loss and damage, affecting patients' mental health.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Sorafenib may cause hair loss in a way similar to alopecia areata.

TNF-alpha inhibitors can cause various immune-related skin issues.

Minoxidil helps hair regrowth by stimulating hair follicles and reducing immune responses.

Red light at 627 nm can safely trigger IL-4 release in skin cells, potentially helping treat inflammatory skin conditions.

Autoimmune reactions may cause both alopecia areata and HAM.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Certain immune cells may cause hair loss by reacting to stressed hair follicles.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.

AIRE-deficient rats developed severe autoimmune disease similar to APECED, useful for testing treatments.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

CGRP may help protect hair follicles from immune system attacks, potentially slowing hair loss.

The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.